complications such as mastectomy indication, incision pattern, reconstruction type, radiation, and tobacco use at time of surgery. Staged and non-staged cohorts were compared with regards to demographics, operative characteristics and reconstructive outcomes.
The non-staged group had significantly more tissue expander reconstructions versus immediate implant reconstructions (24 [75%] versus 8 [24%], respectively) compared to the staged group (6 [37.5%] versus 10 [62.5%], respectively) (p=0.0249). Average mastectomy weight in the staged group was 962.1 grams (range: 544-1690) and 789.6 grams in the non-staged group (range: 540-1420) (p=0.0760). Average follow-up was longer in the nonstaged group (38.5 versus 25.3 months, p=0.0446).
The rate of major ischemic complications (nipple or mastectomy flap necrosis requiring debridement) was significantly lower in the staged cohort (6.3% versus 34.4%, respectively; p=0.0404). The staged cohort also had lower rates of major mastectomy flap necrosis (0% versus 21.9%), full nipple necrosis (6.3% versus 12.5%) and explantation (0% versus 12.5%), though these complications, major/minor infection and minor ischemic complications were comparable between the groups. Two breasts in both the staged (12.5%) and non-staged (6.3%) cohorts required correction of nipple malposition (p=0.5921).
CONCLUSION:
In patients with large breast size, staged breast reduction prior to NSM had significantly lower rates of major ischemic complications compared to non-staged cases after controlling for other risk factors for complications. Staged reduction may be a useful technique for reducing ischemic complications in prophylactic NSM cases with large breast size and an excess skin envelope. 
Comparing the Surgical Outcomes of Prophylactic and Therapeutic

BACKGROUND:
Although prophylactic compared to therapeutic mastectomies followed by reconstruction have been shown to result in improved aesthetics, there has been little research to date examining their comparative surgical outcomes. This study aims to examine the surgical outcomes of patients who underwent mastectomies with immediate reconstruction for breast cancer to patients who underwent the same surgery for prophylactic indications.
METHODS:
A retrospective review of females (age ≥18) who underwent mastectomy with immediate reconstruction between January 2007 and January 2017 at two tertiary care centers was conducted. Patients who underwent immediate reconstruction with autologous implants were excluded. Patients were divided into cohorts based upon whether they underwent a bilateral or unilateral procedure, and whether the procedure was therapeutic or prophylactic. Post-operative complications were compared between the cohorts.
RESULTS:
A total of 318 patients who underwent mastectomy were identified. About half of the study population, 160 patients, underwent bilateral mastectomy for cancer, 29 patients (9%) underwent bilateral mastectomy for prophylaxis, 106 patients (33.3%) underwent unilateral mastectomy for cancer and 23 patients (7%) underwent unilateral mastectomy for prophylaxis. Univariate analysis of data from the bilateral mastectomy with reconstruction cohort showed patients in the therapeutic group had more comorbidities, higher BMIs, and greater ASA scores on average (All p<0.005). Postoperative outcomes were then examined by multivariate analysis, which showed no significant differences in overall complication, reoperation or readmission rates. There was however, a significantly higher surgical-site infection rate within 30-days (p<0.02) and 90-days (p<0.02) in patients who underwent a bilateral prophylactic procedure.
CONCLUSION:
Bilateral mastectomy with immediate reconstruction is a safe procedure when performed for therapeutic or prophylactic reasons. Despite being in overall better health, the prophylactic cohort had higher rates of surgical-site infections. More studies will be needed to elucidate the cause of this increased infection rate.
